Genetic testing for inherited mutations
- Medical Review: Kelsey Spielman, MS, LCGC
Most people diagnosed with breast cancer have no family history of the disease. It happens by chance. But some people carry a genetic change passed down by a parent that increases the risk of breast cancer. This is called an inherited genetic mutation.
Genes are pieces of our DNA that give directions to cells. When genes work properly, they support healthy, functional cells in our bodies. If there is an error in the DNA, a mutation can happen.
Inherited genetic mutations can cause hereditary breast cancer. But most breast cancers are not hereditary. It is more common for non-inherited, or acquired, mutations to lead to breast cancer. Only about five to 10% of all breast cancers are linked to inherited gene mutations.
If you’ve been diagnosed with breast cancer, it’s important to know that:
- A breast cancer diagnosis does not always mean you carry an inherited genetic mutation.
- Most women diagnosed with breast cancer do not have inherited genetic mutations.
- Men diagnosed with breast cancer are more likely to carry an inherited genetic mutation.
If you learn through genetic testing that you carry an inherited genetic mutation, there are options for treating the current breast cancer and reducing the risk of future breast cancers.
Knowing whether you have an inherited genetic mutation can:
- Help you and your doctor choose the most effective treatments for you
- Help you, your family, and your healthcare team make decisions about screening to reduce the risk of a future cancer
If you have never been diagnosed with breast cancer but worry that you may be at increased risk due to an inherited genetic mutation, visit At high risk for breast cancer.
Inherited versus non-inherited gene mutations
Genetic mutations occur in one of two ways: by being passed on to us by our parents, or by developing on their own throughout the course of our lives.
Inherited genetic mutations are passed on by a parent.
- A person is born with this kind of mutation.
- Tests for inherited genetic mutations are typically performed on non-cancer cells such as blood or saliva. A sample is taken and sent to a lab, and the results show whether you carry a known inherited breast cancer gene mutation.
Non-inherited genetic mutations develop on their own, after a person is born. They are sometimes called acquired genetic mutations, somatic mutations, or sporadic mutations. Non-inherited genetic mutations:
- Do not come from your parents and cannot be passed on to your children
- Often form during cell division and multiplication—they are simply mistakes made during the process
- Can sometimes be caused by things in the environment, such as high levels of radiation, but finding their cause is not always possible
- Are a more common cause of cancer than inherited mutations
For people diagnosed with breast cancer, tests can confirm a non-inherited genetic mutation using a sample of tumor tissue or blood.
Knowing if you have an inherited or non-inherited genetic mutation can help you and your care team develop a plan to treat a current cancer or lower the risk of future cancer.
Inherited genetic testing versus genomic testing
You may have heard the term “genomic tests.” It’s important to know that tests for inherited genetic mutations and genomic tests are not the same thing. In breast cancer, genomic tests look at genes in cancer cells for different reasons:
- In early-stage breast cancer, genomic tests look at how gene activity affects the risk of recurrence. These tests are performed on tumor tissue. Learn more about genomic testing in early-stage breast cancer.
- In metastatic breast cancer, genomic tests look at whether there are non-inherited mutations that can be matched with a targeted treatment. These tests often use a technology called next-generation sequencing, which looks at hundreds of genes in tumor tissue or blood.
A genomic test is one of many types of biomarker tests. Learn more about biomarker testing.
Both genetic tests and genomic tests are an important part of personalized medicine, an approach to healthcare that looks at each individual person’s test results, day-to-day life habits, and environment to make decisions about treatments, lifestyle changes, and cancer screening schedules. With this approach, doctors can ensure the most precise treatment and avoid overtreatment.
Inherited gene mutations that increase breast cancer risk
There are several inherited gene mutations that increase the risk of breast cancer. Some are more likely than others to lead to cancer.
Finding out you have an inherited gene mutation linked to cancer can change how frequently you have screening tests. In some cases, an inherited gene mutation can open up new treatment options.
BRCA1 and BRCA2 genetic mutations are the two mutations most associated with hereditary breast cancer. Only a small percentage of all breast cancers are thought to be caused by BRCA mutations. These mutations can also increase the risk of ovarian cancer. Visit Inherited BRCA mutations to learn more, including:
- Signs breast cancer may be BRCA-related
- Understanding BRCA genetic test results
- How a positive result impacts treatment decisions
BRCA1 and BRCA2 mutations are not the only mutations linked to an increased risk of breast cancer. Mutations in the following genes can increase the risk of breast cancer, breast cancer recurrence, and for some, breast cancer developing in the opposite breast:
- ATM
- BARD1
- CDH1
- CHEK2
- PALB2
- PTEN
- RAD51C
- RAD51D
- STK11
- TP53
Learn more about these mutations on the Understanding genetic test results page.
Who should be tested?
For BRCA1 and BRCA2 mutations, the American Society of Clinical Oncology (ASCO) recommends testing if you:
- Are newly diagnosed or were treated for breast cancer in the past and are 65 or younger
- Are older than age 65 and have a personal or family breast cancer history suggestive of an inherited gene mutation (such as triple-negative breast cancer) or are of ancestry with known higher incidence of inherited genetic mutations, such as Ashkenazi Jewish ancestry
- Are 65 or older and meet eligibility requirements to take PARP inhibitor breast cancer treatment
- Have a second breast cancer diagnosis that is not a recurrence of a first breast cancer
- Have breast cancer and are assigned male at birth
ASCO also recommends that certain people be tested for inherited mutations in other genes, including CDH1, PALB2, PTEN, STK11, and TP53, if it can help inform treatment decisions, manage the risk of a new cancer, and confirm personal and family risk.
Read the full ASCO guidelines for genetic testing in people with breast cancer.
The National Comprehensive Cancer Network (NCCN) recommends genetic testing for mutations of BRCA1, BRCA2, CDH1, PALB2, PTEN, STK11, and TP53 if you:
- Have a personal history of breast cancer and are age 50 or younger
- If you are any age and:
- Have a family history that includes close blood relatives with breast cancer at age 50 or younger, male breast cancer, ovarian cancer, pancreatic cancer, or certain prostate cancers
- May be eligible for PARP inhibitor treatment
- Have had a second breast cancer diagnosis that is not a recurrence of a first breast cancer
- Are a man diagnosed with breast cancer
- Have triple-negative or lobular breast cancer plus a personal or family history of a certain type of stomach cancer
- Are of Ashkenazi Jewish ancestry
Read the complete NCCN guidelines for genetic testing in people with breast cancer.
Having a family member who carries a gene mutation greatly increases the chance that you also carry a gene mutation. Your test results may help other relatives including parents, siblings, children, grandchildren, or cousins decide whether they should seek genetic counseling to discuss possible testing.
Should I consider genetic testing for an inherited mutation?
A genetic counselor can help you understand whether your family history increases the chance that you may have an inherited genetic mutation. Consider meeting with a genetic counselor if any of the ASCO or NCCN guidelines above apply to you.
If your doctor does not talk with you about genetic counseling or testing, it’s OK to start the conversation yourself and ask for a referral to a genetic counselor. Learn more about genetic counseling.
Re-testing if you had testing in the past
If you were tested for an inherited gene mutation many years ago, ask your doctor or genetic counselor if getting tested again would be beneficial for you. Today’s genetic tests can look for more mutations in more genes than they could a decade ago. It’s possible current tests may show you carry a gene mutation that was unknown before, especially if your past results were uncertain.
Types of genetic tests
There are several types of tests to search for inherited mutations that can cause breast cancer. Testing can be done in a few different ways. Your genetic counselor can explain which type of testing is best for you.
Depending on your personal and family history of cancer, and whether a gene mutation has been identified in your family in the past, your counselor may recommend testing of BRCA1 and BRCA2. They may also recommend testing for other genes or for a panel of genes.
The three most common tests are:
- Comprehensive testing of BRCA1 and BRCA2 with the option of including PALB2
- Single-site or single-gene testing for a mutation already known to be in your family
- Gene panel tests, which look for many mutations in many genes all at once; these tests can focus on genes associated with breast cancer or genes associated with breast and other cancers
How genetic testing works
If you’ve been diagnosed with breast cancer, talk with your oncologist about genetic counseling and testing and whether it may be helpful for you.
Deciding to get genetic counseling
Genetic counseling is not required to get genetic testing for an inherited mutation. But meeting with a genetic counselor is an important and helpful way to think through whether your personal or family history of breast cancer suggests genetic testing is right for you.
Genetic counselors are professionals trained in risk assessment and in explaining your test results. They can also:
- Talk with you about how to share test results with your family
- Provide guidance on talking with your oncologist about managing risk
If your doctor hasn’t referred you to a genetic counselor, ask to be referred. It's also possible to meet with a genetic counselor without a doctor giving a referral, but it’s important to check with your insurance company first. In some cases, your insurance won’t cover counseling services unless a doctor submits a referral.
You can meet with a genetic counselor in person if they’re available in your area. Many hospitals also have options to meet a genetic counselor by phone or video appointment (telehealth).
To find a genetic counselor in your area or a genetic counselor who can offer telehealth services, visit the National Society of Genetic Counselors website.
If genetic counseling is not available to you, your oncologist can order genetic testing for you. Some oncologists have additional training in reading genetic test results.
Informed consent for genetic testing
If you decide to move forward with genetic testing for an inherited mutation, you’ll be asked to give informed consent before the test.
To give informed consent, you’ll sign a form that says:
- You understand the genetic testing process and that you had the opportunity to ask questions.
- You understand that you have a choice about whether you get the test.
To learn more about the informed consent process, visit The American Cancer Society.
Giving a blood or saliva sample
After you sign the genetic testing informed consent form, you will provide a blood or saliva sample.
Genetic testing with a blood sample: Blood may be drawn at a lab or at your doctor’s office or a hospital, and then sent to a lab for testing. The blood is taken by needle, usually from a vein on the inside of your elbow.
Genetic testing with a saliva sample: If you are offered a saliva collection kit, you will collect your sample on your own, at home. You will spit into a cup after following instructions provided to you and then mail the sample to the lab or drop it off at your doctor’s office for them to send on your behalf.
The lab will then search for gene mutations.
Getting genetic test results
A results report will be sent to your doctor or genetic counselor. It may take several weeks for your test results to come back. If you need your results sooner to make treatment decisions, ask your healthcare team if they can rush the results.
When your care team receives your test results, they’ll schedule time to talk with you about what they mean and how they may impact treatment, screening schedules, and lowering the risk of future cancers. Make sure to ask for a copy.
Learn more about Understanding genetic test results.
Sharing results with family
Sometimes, family dynamics can make it hard to discuss topics like possible shared inherited gene mutations. For tips on how to share test results with family, visit Sharing your inherited genetic test results.
Paying for genetic testing
The cost of genetic testing for an inherited mutation can be different depending on the mutation and your insurance coverage.
Paying for inherited BRCA mutation testing
Under the Affordable Care Act, most private insurance companies are required to pay the total cost of BRCA testing for people who meet eligibility requirements, with no out-of-pocket costs. If you don’t fully meet the requirements needed under the ACA, many insurance companies will still pay a portion of the cost, and you will pay some out-of-pocket fees.
If you have Medicaid or Medicare, the requirements for coverage are different. Your genetic counselor can review the cost of testing with you before you have the test.
If you don’t have insurance or insurance won’t cover the cost of testing, paying out-of-pocket for BRCA testing can cost $250 or more. Some labs and cancer centers offer financial assistance or payment plans to people who are uninsured. Be sure to ask your genetic counselor for help with these resources.
Paying for other inherited mutation testing
The Affordable Care Act does not require insurers to help pay for genetic testing to look for inherited mutations in non-BRCA cancer-related genes, such as CDH1, PALB2, and PTEN—even though they are included in testing guidelines. Still, it’s possible your insurance will help cover some of the cost. Talk to your genetic counselor and call your insurance company to find out.
Family members’ genetic testing costs
If you test positive for an inherited high-risk cancer mutation, your family members’ insurance providers may be more likely to cover the cost of their genetic testing. If family members are interested in testing, encourage them to check with their health insurance companies about coverage.
To learn more about financial support and paying for care, visit Financial matters.
How clinical trials can help if you test positive
If you test positive for an inherited genetic mutation and decide to participate in a clinical trial studying the mutation, you may be able to have low- or no-cost access to a new treatment. You can also help researchers:
- Understand more about how mutated genes can lead to breast cancer
- Develop new breast cancer treatments targeted to cancers in people with inherited mutations
Learn more about participating in clinical trials.
A note on at-home testing
You may see at-home genetic tests advertised on TV or available online. They can be delivered directly to you by mail and don’t need to be ordered by a doctor or other healthcare professional.
An at-home genetic test may require you to visit a health clinic to have a blood sample taken and sent to the lab that sells the test, or it may only ask you to send a saliva sample to the lab by mail, without seeing a doctor first.
An at-home test may cost less or feel like less of a burden because it requires fewer doctor appointments. But if you choose at-home testing, you won’t have guidance from a genetic counselor.
Having a genetic counselor ensures that:
- You’re getting the right tests for your risk profile.
- You know the next steps if you test positive for a gene mutation.
Genetic counselors are also trained in helping you navigate emotions that may come up once your results are back, and in helping you prepare to share your result with family if you choose to do so.
If you have questions or concerns about at-home testing versus testing at your hospital, talk with your oncologist, or ask to speak with a social worker, genetic counselor, or patient navigator.
Related downloads
View all downloadsStay connected
Sign up to receive emotional support, medical insight, personal stories, and more, delivered to your inbox weekly.
- 3-dimensional radiation therapy
- 4-hydroxytamoxifen
- ablation
- abnormal
- Abraxane
- absolute risk
- AC regimen
- AC-T regimen
- AC-T-T regimen
- AC-Taxol regimen
- AC-TH regimen
- accelerated partial-breast irradiation
- action study
- acupoint
- acupressure
- acupuncture
- acupuncture needle
- acupuncture point
- acupuncture point injection
- acupuncturist
- acustimulation
- acute
- acute pain
- adenocarcinoma
- adenopathy
- adenosis
- adjunct agent
- adjunct therapy
- adjunctive therapy
- adjuvant therapy
- advance directive
- advanced practice nurse
- adverse effect
- aerobic exercise
- agent study
- aggravating factor
- aggressive
- AJCC staging system
- Alkeran
- alkylating agent
- Allegra
- allopathic medicine
- alopecia
- amifostine
- aminoglutethimide
- amitriptyline
- anabolic steroid
- analgesic
- anaplastic
- anastrozole
- ancillary test
- anemia
- anesthesia
- anesthesiologist
- angiogenesis
- angiogenesis inhibitor
- antagonist
- anthracycline
- anti-anxiety medicine
- anti-idiotype vaccine
- anti-inflammatory
- antibody-dependent cellular cytotoxicity
- antibody therapy
- anticachexia
- anticancer antibiotic
- anticancer therapy
- anticonvulsant
- antidepressant
- antiemetic
- antiestrogen
- antifolate
- antigen-presenting cell vaccine
- antihormone therapy
- antimetabolite
- antimitotic agent
- antineoplastic
- antitumor
- anxiety
- anxiolytic
- Anzemet
- APN
- apocrine gland
- apoptosis
- aprepitant
- areola
- Aromasin
- aromatase inhibitor
- aromatherapy
- arthralgia
- ascites
- aspirate
- aspiration
- assay
- asthenia
- asymptomatic
- atypia
- atypical ductal hyperplasia
- atypical hyperplasia
- atypical lobular hyperplasia
- avoidance
- axillary lymph node
- axillary lymph node dissection
- BAK gel
- balloon catheter radiation
- baseline
- behavior modification
- best practice
- BI-RADS
- Biafine cream
- bias
- bilateral
- bilateral breast cancer
- bilateral prophylactic mastectomy
- bilateral salpingo-oophorectomy
- biofeedback
- biologic
- biopsy
- biopsy specimen
- biotherapy
- bisphosphonate
- bisphosphonate-associated osteonecrosis
- blinded study
- blood-brain barrier
- blood-brain barrier disruption
- blood cell count
- blood chemistry study
- board certified oncology pharmacy specialist
- body image
- body mass index
- bolus dose
- bone density
- bone metastasis
- bone mineral density scan
- bone scan
- bone-seeking radioisotope
- brachytherapy
- brain metastasis
- BRCA1
- BRCA2
- BRCAPro
- breast carcinoma in situ
- breast-conserving surgery
- breast density
- breast duct
- breast duct endoscopy
- breast lobe
- breast lobule
- breast reconstruction
- breast self-exam
- Brief Pain Inventory
- cachexia
- CAF regimen
- calcification
- cancer vaccine
- candidiasis
- capecitabine
- carboplatin
- carcinogen
- carcinoma
- carcinoma in situ
- carcinomatous meningitis
- carcinosis
- carcinostatic
- cardiotoxicity
- caregiver
- carmustine
- case-control study
- case report
- case series
- CAT scan
- CBC
- cell
- cell-cycle regulation
- cell proliferation
- central nervous system
- central nervous system metastasis
- central nervous system prophylaxis
- central venous access catheter
- cetuximab
- cevimeline
- chaplain
- charged-particle radiation therapy
- chemoembolization
- chemoimmunotherapy
- chemoprevention
- chemoprevention study
- chemoprotective
- chemoradiation
- chemosensitivity
- chemosensitivity assay
- chemosensitizer
- chemotherapeutic agent
- chemotherapy
- chest wall
- chest X-ray
- Chinese meridian theory
- chronic
- chronic pain
- cisplatin
- Claus model
- clergy
- clinical
- clinical breast exam
- clinical practice guidelines
- clinical researcher
- clinical resistance
- clinical series
- clinical stage
- clinical staging
- clinical study
- clinical trial
- clinician
- clodronate
- CMF regimen
- cognition
- cognitive behavior therapy
- cognitive therapy
- cohort
- cohort study
- coinsurance
- combination chemotherapy
- comedo carcinoma
- comfort care
- Coming Out
- Community Advisory Board
- comorbidity
- compassionate use trial
- complementary and alternative medicine
- complementary medicine
- complete metastasectomy
- complete remission
- complete response
- complex decongestive therapy
- compliance
- complication
- compression garment
- computed tomography scan
- concomitant
- concurrent therapy
- condition
- consolidation therapy
- constitutional acupuncture
- continuum of care
- contract research organization
- contraindication
- contralateral
- contrast material
- control group
- controlled clinical trial
- controlled study
- conventional medicine
- conventional therapy
- copayments
- cope
- coping skills
- core biopsy
- core needle biopsy
- corticosteroid
- counseling
- COX inhibitor
- cryoablation
- cryopreservation
- cryosurgery
- CT scan
- cultural competency
- cumulative dose
- cumulative exposure
- cure
- cutaneous
- cutaneous breast cancer
- cyclophosphamide
- cyclosporine
- CYP2D6 inhibitor
- cystosarcoma phyllodes
- cytopenia
- cytotoxic
- cytotoxic chemotherapy
- Cytoxan
- Data and Safety Monitoring Board
- DCIS
- de novo
- debulking
- deductible
- definitive surgery
- definitive treatment
- dehydration
- denosumab
- depression
- diagnosis
- diagnostic mammogram
- diagnostic procedure
- diagnostic technique
- diagnostic trial
- diameter
- diarrhea
- diaziquone
- DIEP flap
- dietary counseling
- dietary supplement
- dietitian
- differentiation
- diffuse
- digital mammography
- diphenhydramine
- discharge
- disease progression
- disease-specific survival rate
- distant cancer
- distant metastasis
- Distant recurrence
- distress
- DNR order
- docetaxel
- dolasetron
- dose
- dose-dense chemotherapy
- dose-dependent
- dose-limiting
- dose-rate
- double-blinded
- doxorubicin
- drain
- dronabinol
- droperidol
- drug interaction
- drug resistance
- drug therapy
- drug tolerance
- duct
- ductal carcinoma
- ductal carcinoma in situ
- ductal lavage
- duloxetine
- durable power of attorney
- dysfunction
- dysgeusia
- dyspepsia
- dyspnea
- early menopause
- early-stage breast cancer
- edema
- EEG biofeedback
- efficacy
- Eklund displacement views
- electroacupuncture
- electron beam
- eligibility criteria
- Ellence
- emesis
- emetic
- endocrine
- endocrine therapy
- endpoint
- energy healing
- enteral nutrition
- epidemiology
- epirubicin
- ER+
- ER-
- ER
- ER-PR-HER2/neu-
- eribulin mesylate
- erythema
- estradiol
- estrogen
- estrogen blocker
- estrogen receptor
- estrogen receptor-negative
- estrogen receptor-positive
- estrogen receptor test
- estrogen replacement therapy
- etanidazole
- etidronate
- everolimus
- Evista
- excision
- excisional biopsy
- exemestane
- expanded access trial
- experimental
- extranodal
- false-negative test result
- false-positive test result
- familial cancer
- family medical history
- Faslodex
- fast-neutron beam radiation
- fatigue
- FDA
- febrile neutropenia
- FEC regimen
- Femara
- fertility
- fexofenadine
- fibroadenoma
- fibrocystic breast changes
- fiducial marker
- film mammography
- fine-needle aspiration biopsy
- first-degree relative
- first-line therapy
- five-year survival rate
- fluorouracil
- fluoxetine
- FNA biopsy
- focal
- Food and Drug Administration
- Fosamax
- fractionation
- fulvestrant
- functional magnetic resonance imaging
- gadolinium
- Gail model
- gallium scan
- gamma irradiation
- Gamma Knife therapy
- gamma ray
- Gelclair
- gemcitabine
- gene
- gene expression profile
- gene therapy
- general anesthesia
- generalized anxiety disorder
- generic
- genetic
- genetic counseling
- genetic marker
- genetic marker of susceptibility
- genetic predisposition
- genetic profile
- genetic susceptibility
- genetic testing
- genetic testing
- genetics
- genome
- genome-wide association study
- genomic profile
- genomic test
- genomics
- gland
- Good Clinical Practice
- goserelin
- grade
- grading
- granisetron
- gross description
- Halaven
- hazard ratio
- healing touch
- Health Insurance Portability and Accountability Act
- healthcare provider
- healthcare proxy
- healthy control
- helical computed tomography
- HER2/neu
- Herceptin
- hereditary
- hereditary mutation
- heteronormative
- high-dose chemotherapy
- high-dose radiation
- high-energy proton therapy
- high grade
- high-risk cancer
- HIPPA
- histologic examination
- histology
- historic cohort study
- historical control subject
- homeopathic medicine
- hormonal therapy
- hormone
- hormone receptor
- hormone receptor test
- hormone replacement therapy
- hormone responsive
- hormone therapy
- hospice
- hot flash
- human epidermal growth factor receptor 2
- human participant protection regulations
- hydroxydaunorubicin
- hyperalimentation
- hypercalcemia
- hyperfractionated radiation therapy
- hyperfractionation
- hyperplasia
- hypersensitivity
- hypofractionated radiation therapy
- hypofractionation
- hypoxia
- ibandronate
- ibuprofen
- idiopathic
- image-guided radiation therapy
- imaging
- imaging procedure
- immune adjuvant
- immune function
- immune response
- immune system
- immune system tolerance
- immunization
- immunoassay
- immunocompromised
- immunodeficiency
- immunohistochemistry
- immunology
- immunomodulation
- immunosuppression
- immunotherapy
- implant
- implant displacement views
- implant radiation therapy
- implantable pump
- in network
- in situ
- incidence
- incision
- incisional biopsy
- indication
- indolent
- induction therapy
- infection
- infertile
- infertility
- infiltrating breast cancer
- infiltrating ductal carcinoma
- inflammation
- inflammatory breast cancer
- informed consent
- infusion
- ingestion
- inherited
- iniparib
- injection
- inoperable
- insomnia
- Institutional Review Board
- intensification therapy
- intensity-modulated radiation therapy
- interfering thought
- internal mammary lymph nodes
- internal radiation therapy
- International Unit
- internist
- interstitial radiation therapy
- intervention
- intervention group
- intra-arterial
- intracarotid infusion
- intradermal
- intraductal breast papilloma
- intraductal carcinoma
- intrahepatic
- intrahepatic infusion
- intramuscular
- intramuscular injection
- intraoperative radiation therapy
- intraoperative ultrasound
- intratumoral
- intravasation
- intravenous
- intravenous infusion
- intravenous injection
- intrusive thought
- intrusive thoughts
- invasive breast cancer
- invasive cancer
- invasive procedure
- investigational
- investigator
- ionizing radiation
- ipsilateral
- IRB
- irradiated
- irradiation
- irreversible toxicity
- ixabepilone
- joint pain
- Karnofsky Performance Status
- laboratory test
- lapatinib
- laser
- laser surgery
- laser therapy
- lassitude
- late effects
- late-stage cancer
- latent
- laxative
- LEEP
- legal aid organization
- lesion
- lethargy
- letrozole
- leukopenia
- levels of evidence
- Lexapro
- libido
- lidocaine
- ligation
- linac
- linear accelerator
- lipoma
- lisofylline
- liver metastasis
- liver scan
- living will
- lobaplatin
- lobe
- lobectomy
- lobular carcinoma
- lobular carcinoma in situ
- lobule
- local anesthesia
- local cancer
- local therapy
- localization
- localized
- locally advanced cancer
- locally recurrent cancer
- lomustine
- loop electrosurgical excision procedure
- loop excision
- lorazepam
- low grade
- lubricant
- lumbar puncture
- lumpectomy
- lung metastasis
- luteinizing hormone-releasing hormone agonist
- lymph
- lymph gland
- lymph node
- lymph node dissection
- lymph node drainage
- lymph node mapping
- lymph vessel
- lymphadenectomy
- lymphadenopathy
- lymphangiogram
- lymphangiography
- lymphatic basin
- lymphatic fluid
- lymphatic mapping
- lymphatic system
- lymphatic vessel
- lymphedema
- lymphography
- lymphoscintigraphy
- Lyrica
- lytic lesion
- macrocalcification
- magnetic resonance imaging
- magnetic resonance perfusion imaging
- magnetic resonance spectroscopic imaging
- mainstream medicine
- maintenance therapy
- male breast cancer
- malignancy
- malignant
- malignant pleural effusion
- malnutrition
- mammary
- mammary dysplasia
- mammary gland
- mammogram
- mammography
- MammoSite
- Mammotome
- mantle field
- MAO inhibitor
- margin
- marker
- mass
- massage therapy
- mastectomy
- mastitis
- maternal
- maximum tolerated dose
- mean survival time
- measurable disease
- medial supraclavicular lymph node
- median
- median survival time
- Medicaid
- medical castration
- medical device
- medical nutrition therapy
- medical oncologist
- Medicare
- medicine
- medullary breast carcinoma
- mega-voltage linear accelerator
- megestrol
- melphalan
- meningeal metastasis
- menopause
- menorrhagia
- menstrual cycle
- menstrual period
- menstruation
- mental health
- mental health counselor
- meridian
- mesna
- meta-analysis
- metallic
- metastasectomy
- metastasis
- metastasize
- metastatic
- methotrexate
- metoclopramide
- metronomic therapy
- microcalcification
- micrometastasis
- microscopic
- milk duct
- mind/body exercise
- mindfulness relaxation
- Miraluma test
- mitigate
- modified radical mastectomy
- molecular marker
- molecular medicine
- molecular risk assessment
- molecularly targeted therapy
- monoamine oxidase inhibitor
- monoclonal antibody
- morbidity
- mortality
- MRI
- MRSI
- MTD
- mTOR
- mucositis
- multicenter study
- multicentric breast cancer
- multidisciplinary
- multidisciplinary opinion
- multidrug resistance
- multidrug resistance inhibition
- multifocal breast cancer
- music therapy
- mutation
- mutation carrier
- myalgia
- myelosuppression
- nanoparticle paclitaxel
- narcotic
- National Cancer Institute
- National Center for Complementary and Alternative Medicine
- National Institutes of Health
- natural history study
- naturopathy
- nausea
- NCCAM
- NCI
- NCI clinical trials cooperative group
- needle biopsy
- needle localization
- needle-localized biopsy
- negative axillary lymph node
- negative test result
- neoadjuvant therapy
- neoplasm
- nerve
- nerve block
- neurocognitive
- neurologic
- neuropathy
- neurotoxicity
- neurotoxin
- neutropenia
- NIH
- nipple
- nipple discharge
- nitrosourea
- NMRI
- node-negative
- node-positive
- nodule
- nonblinded
- nonconsecutive case series
- noninvasive
- nonmalignant
- nonmetastatic
- nonprescription
- nonrandomized clinical trial
- nonsteroidal anti-inflammatory drug
- nonsteroidal aromatase inhibitor
- nontoxic
- normal range
- normative
- NP
- NPO
- NSAID
- nuclear grade
- nuclear magnetic resonance imaging
- nuclear medicine scan
- nurse
- nurse practitioner
- nutrition
- nutrition therapy
- nutritional counseling
- nutritional status
- nutritional supplement
- nutritionist
- obese
- objective improvement
- objective response
- observation
- observational study
- obstruction
- off-label
- olaparib
- oncologist
- oncology
- oncology nurse
- oncology pharmacy specialist
- oncolysis
- ondansetron
- onset of action
- oophorectomy
- open biopsy
- open label study
- open resection
- operable
- opiate
- opioid
- opportunistic infection
- oral
- organ
- orthodox medicine
- osteolytic
- osteonecrosis of the jaw
- osteopenia
- osteoporosis
- OTC
- out of network
- outcome
- outpatient
- ovarian
- ovarian ablation
- ovarian cancer
- ovarian suppression
- ovary
- over-the-counter
- overall survival rate
- overdose
- overexpress
- overweight
- ovulation
- PA
- paclitaxel
- paclitaxel albumin-stabilized nanoparticle formulation
- paclitaxel-loaded polymeric micelle
- Paget disease of the nipple
- pain threshold
- palliation
- palliative care
- palliative therapy
- palmar-plantar erythrodysesthesia
- palonosetron hydrochloride
- palpable disease
- palpation
- palpitation
- pamidronate
- panic
- papillary tumor
- Paraplatin
- parenteral nutrition
- paroxetine hydrochloride
- PARP
- PARP inhibitor
- partial-breast irradiation
- partial mastectomy
- partial oophorectomy
- partial remission or partial response
- pastoral counselor
- paternal
- pathologic fracture
- pathological stage
- pathological staging
- pathologist
- pathology report
- patient advocate
- Paxil
- peau d'orange
- pedigree
- peer-review process
- peer-reviewed scientific journal
- perfusion magnetic resonance imaging
- perimenopausal
- periodic neutropenia
- perioperative
- peripheral neuropathy
- peripheral venous catheter
- personal health record
- personal medical history
- personalized medicine
- Pertuzumab
- PET scan
- pharmacist
- phase I/II trial
- phase I trial
- phase II/III trial
- phase II trial
- phase III trial
- phase IV trial
- phlebotomy
- photon beam radiation therapy
- phyllodes tumor
- physical examination
- physical therapist
- physical therapy
- physician
- physician assistant
- physiologic
- PI3 kinase inhibitor
- pilocarpine
- pilot study
- placebo
- placebo-controlled
- plastic surgeon
- plastic surgery
- population study
- positive axillary lymph node
- positive test result
- positron emission tomography scan
- post-traumatic stress disorder
- postmenopausal
- postoperative
- postremission therapy
- potentiation
- power of attorney
- PR
- PR+
- PR-
- practitioner
- preauthorization
- precancerous
- preclinical study
- predictive factor
- pregabalin
- premalignant
- premature menopause
- premenopausal
- premium
- prescription
- prevention
- preventive
- preventive mastectomy
- primary care
- primary care doctor
- primary endpoint
- primary therapy
- primary treatment
- primary tumor
- Principal investigator
- prochlorperazine
- progesterone
- progesterone receptor
- progesterone receptor-negative
- progesterone receptor-positive
- progesterone receptor test
- progestin
- prognosis
- prognostic factor
- progression
- progression-free survival
- progressive disease
- Prolia
- proliferative index
- promegapoietin
- prophylactic
- prophylactic mastectomy
- prophylactic oophorectomy
- prophylactic surgery
- prophylaxis
- prospective
- prospective cohort study
- prosthesis
- protective factor
- protein
- protein-bound paclitaxel
- protein expression
- protein expression profile
- protocol
- proton
- proton magnetic resonance spectroscopic imaging
- pruritus
- psychiatrist
- psychological
- psychologist
- psychosocial
- psychotherapy
- PTSD
- pump
- punch biopsy
- qi
- qigong
- quadrantectomy
- quality assurance
- quality of life
- radiation
- radiation brachytherapy
- radiation dermatitis
- radiation fibrosis
- radiation necrosis
- radiation nurse
- radiation oncologist
- radiation physicist
- radiation surgery
- radiation therapist
- radiation therapy
- radical lymph node dissection
- radical mastectomy
- radioactive
- radioactive drug
- radioactive seed
- radioisotope
- radiologic exam
- radiologist
- radiology
- radionuclide
- radionuclide scanning
- radiopharmaceutical
- radiosensitization
- radiosensitizer
- radiosurgery
- radiotherapy
- raloxifene
- raloxifene hydrochloride
- randomization
- randomized clinical trial
- receptor
- RECIST
- reconstructive surgeon
- reconstructive surgery
- recreational therapy
- recurrence
- recurrent cancer
- referral
- reflexology
- refractory
- refractory cancer
- regimen
- regional
- regional anesthesia
- regional cancer
- regional chemotherapy
- regional lymph node
- regional lymph node dissection
- registered dietician
- regression
- rehabilitation
- rehabilitation specialist
- relapse
- relative survival rate
- relaxation technique
- remission
- remission induction therapy
- remote brachytherapy
- research nurse
- research study
- resectable
- resected
- resection
- residual disease
- resistant cancer
- resorption
- respite care
- response rate
- retrospective cohort study
- retrospective study
- risk factor
- Rubex
- salpingo-oophorectomy
- salvage therapy
- samarium 153
- sargramostim
- scalpel
- scan
- scanner
- scintigraphy
- scintimammography
- sclerosing adenosis
- screening
- screening mammogram
- second-line therapy
- second-look surgery
- second primary cancer
- secondary cancer
- secrete
- sedative
- segmental mastectomy
- selection bias
- selective estrogen receptor modulator
- selective serotonin reuptake inhibitor
- sentinel lymph node
- sentinel lymph node biopsy
- sentinel lymph node mapping
- sepsis
- sequential AC/Taxol-Trastuzumab regimen
- sequential treatment
- SERM
- sertraline
- Serzone
- sestamibi breast imaging
- sexuality
- sibling
- side effect
- silicone
- simple mastectomy
- simulation
- Single-agent therapy
- sleep disorder
- social service
- social support
- social worker
- sodium thiosulfate
- soft tissue
- solid tumor
- somatic
- somatic mutation
- sorafenib
- specialist
- specificity
- spiculated mass
- spinal anesthesia
- spinal block
- spiral CT scan
- spirituality
- sporadic cancer
- SSRI
- stable disease
- stage
- stage 0 breast carcinoma in situ
- stage 0 disease
- stage I breast cancer
- stage IA breast cancer
- stage IB breast cancer
- stage II breast cancer
- stage II breast cancer
- stage IIA breast cancer
- stage IIB breast cancer
- stage III breast cancer
- stage III lymphedema
- stage IIIA breast cancer
- stage IIIB breast cancer
- stage IIIC breast cancer
- stage IV breast cancer
- staging
- stamina
- standard of care
- standard therapy
- statistically significant
- stent
- stereotactic biopsy
- stereotactic radiosurgery
- sterile
- sternum
- steroid
- stress
- strontium
- study agent
- subcutaneous
- subcutaneous port
- subjective improvement
- subset analysis
- supplemental nutrition
- supplementation
- support group
- supportive care
- supraclavicular lymph node
- surgeon
- surgery
- surgical biopsy
- surgical menopause
- surgical oncologist
- survival rate
- symptom
- symptom management
- symptomatic
- synergistic
- synthetic
- syringe
- systemic
- systemic chemotherapy
- systemic disease
- systemic therapy
- TAC regimen
- tai chi
- tailored intervention
- talk therapy
- tamoxifen
- targeted therapy
- taxane
- Taxol
- Taxotere
- Tc 99m sulfur colloid
- technician
- terminal disease
- therapeutic
- therapeutic touch
- therapy
- thermography
- thiethylperazine
- thiotepa
- third-line therapy
- thrush
- time to progression
- tinnitus
- tissue
- tissue flap reconstruction
- TNM staging system
- tomography
- tomotherapy
- topical
- topical chemotherapy
- topoisomerase inhibitor
- total estrogen blockade
- total mastectomy
- total nodal irradiation
- total parenteral nutrition
- toxic
- toxicity
- tracer
- traditional acupuncture
- tranquilizer
- transdermal
- transfusion
- transitional care
- translational research
- trastuzumab
- trauma
- treatment field
- trigger
- trigger point acupuncture
- triple-negative breast cancer
- tumescent mastectomy
- tumor
- tumor antigen vaccine
- tumor board review
- tumor burden
- tumor debulking
- tumor load
- tumor marker
- tumor volume
- Tykerb
- ulcer
- ulceration
- ultrasound-guided biopsy
- ultrasound/ultrasonography
- ultraviolet radiation therapy
- uncontrolled study
- undifferentiated
- unilateral
- unilateral salpingo-oophorectomy
- unresectable
- unresected
- upstaging
- urticaria
- VACB
- vaccine therapy
- vacuum-assisted biopsy or vacuum-assisted core biopsy
- Valium
- vancomycin
- vandetanib
- vascular endothelial growth factor-antisense oligonucleotide
- vascular endothelial growth factor receptor tyrosine kinase inhibitor
- vein
- Velban
- venipuncture
- venous sampling
- Versed
- vertebroplasty
- vinorelbine
- vital
- vomit
- watchful waiting
- wedge resection
- Wellcovorin
- Western medicine
- WGA study
- white blood cell
- whole cell vaccine
- whole genome association study
- wide local excision
- wire localization
- wound
- X-ray therapy
- Xanax
- Xeloda
- xerostomia
- Xgeva
- yoga
- ziconotide
- Zinecard
- Zofran
- zoledronic acid
- Zoloft
- Zometa
Living Beyond Breast Cancer is a national nonprofit organization that seeks to create a world that understands there is more than one way to have breast cancer. To fulfill its mission of providing trusted information and a community of support to those impacted by the disease, Living Beyond Breast Cancer offers on-demand emotional, practical, and evidence-based content. For over 30 years, the organization has remained committed to creating a culture of acceptance — where sharing the diversity of the lived experience of breast cancer fosters self-advocacy and hope. For more information, learn more about our programs and services.